Biotech Values

[microcapfun]

Incyte

>>I wish them the best in their CCR5 efforts—as long as they don’t get into the NNRTI arena<<

Incyte got some pretty good P2 results and then stopped development and said they would outlicense that one and concentrate on the rest of their pipeline - especially their JAK inhibitor program.

Seems to be too many CCR5 antagonists out there. Not sure they will be successful finding a buyer. It's been a few months already ...

micro